Earnings Per Share

3 Months Ended

Mar. 31, 2026

AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive.

The following table summarizes the impact of the two-class method:


	Three months ended March 31,
(in millions, except per share data)	2026		2025
Basic EPS
Net earnings attributable to AbbVie Inc.	$	695	$	1,286
Earnings allocated to participating securities	10		10
Earnings available to common shareholders	$	685	$	1,276
Weighted-average basic shares outstanding	1,770		1,768
Basic earnings per share attributable to AbbVie Inc.	$	0.39	$	0.72

Diluted EPS
Net earnings attributable to AbbVie Inc.	$	695	$	1,286
Earnings allocated to participating securities	10		10
Earnings available to common shareholders	$	685	$	1,276
Weighted-average shares of common stock outstanding	1,770		1,768
Effect of dilutive securities	4		4
Weighted-average diluted shares outstanding	1,774		1,772
Diluted earnings per share attributable to AbbVie Inc.	$	0.39	$	0.72

Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.